申请人:CADILA HEALTHCARE LIMITED
公开号:US20170320862A1
公开(公告)日:2017-11-09
The present invention relates to Brexpiprazole having a purity of about 99.5% or more by area percentage of HPLC, having total impurities not more than 0.5% relative to brexpiprazole as measured by area percentage of HPLC, and having less than 0.1% 1-(benzo[b]thiophen-4-yl)piperazine or a salt thereof relative to brexpiprazole by area percentage of HPLC. The present invention also provides a composition comprising brexpiprazole having 1-(benzo[b]thiophen-4-yl)-piperazine or a salt thereof in an amount less than about 0.1% relative to brexpiprazole by area percentage of HPLC and process for the preparation of brexpiprazole.
本发明涉及具有高效液相色谱面积百分比约为99.5%或更高纯度的布瑞匹赛尔,相对于布瑞匹赛尔的总杂质不超过高效液相色谱面积百分比0.5%的测量值,并且相对于布瑞匹赛尔的高效液相色谱面积百分比小于0.1%的1-(苯并[b]噻吩-4-基)哌嗪或其盐。本发明还提供了一种包含布瑞匹赛尔的组合物,其中1-(苯并[b]噻吩-4-基)-哌嗪或其盐的含量相对于布瑞匹赛尔的高效液相色谱面积百分比小于约0.1%,以及布瑞匹赛尔的制备方法。